Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Apr 24, 2026; 17(4): 115287
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.115287
Published online Apr 24, 2026. doi: 10.5306/wjco.v17.i4.115287
Longitudinal microRNA profiles in breast cancer tissue and plasma: Associations with hormone receptors, response, and survival
Dinara Ryspayeva, Legorreta Cancer Center, Brown University, Providence, RI 02903, United States
Dinara Ryspayeva, Attila A Seyhan, Connor Purcell, William J MacDonald, Wafik S El-Deiry, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, The Warren Alpert Medical School, Brown University, Providence, RI 02903, United States
Dinara Ryspayeva, Attila A Seyhan, Connor Purcell, William J MacDonald, Wafik S El-Deiry, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI 02903, United States
Dinara Ryspayeva, Ivan Smolanka Sr, Research Department of Breast Tumors and Recon
Attila A Seyhan, Connor Purcell, William J MacDonald, Wafik S El-Deiry, Legorreta Cancer Center at Brown University, Brown University, Providence, RI 02903, United States
Attila A Seyhan, The Joint Program in Cancer Biology, Brown University and Brown University Health, RI, Providence 02903, United States
Kaizhong Mu, Mengyue Liu, School of Public Health Biostatistics, Brown University, Pro
William J MacDonald, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, United States
Volodymyr Halytskiy, Molecular Biology, Institute of Molecular Biology and Genetics National Academy of Sciences of Ukraine, Kyiv 03143, Ukraine
Tetiana Drevytska, Department of Biology, Bogomoletz Institute of Physiology, Kyiv 01024, Ukraine
Mariia Inomistova, Oncology Diagnostics Laboratory, University Children’s Hospital Zurich - Eleonore Foundation, Zurich 8032, Switzerland
Mariia Inomistova, Natalia Khranovska, Research Laboratory of Experimental Oncology, Na
Oleksandr Potorocha, Lesia Taran, Research Department of Pathological Anatomy and Cyto
Olena Sumkina, Department of Medical Statistics and National Cancer Registry of Ukraine, National Cancer Institute of Ukraine, Kyiv 03022, Ukraine
Wafik S El-Deiry, Hematology-Oncology Division, Department of Medicine, Rhode Island Hospital, Brown University, Providence, RI 02903, United States
Wafik S El-Deiry, The Joint Program in Cancer Biology, Brown University and Brown University Health, Providence, RI 02903, United States
Co-corresponding authors: Dinara Ryspayeva and Attila A Seyhan.
Author contributions: Ryspayeva D, Seyhan AA, and Purcell C wrote the manuscript; Ryspayeva D and Seyhan AA contributed equally to this manuscript as co-corresponding authors; Ryspayeva D, Seyhan AA, and Halytskiy V conceived and designed the study; Ryspayeva D, Inomistova M, Potorocha O, Taran L, and Sumkina O performed material preparation and data acquisition; Mu K, Liu M, Drevytska T, Inomistova M, Khranovska N, and Sumkina O contributed to data processing and analysis; Mu K and Liu M performed statistical analyses; Ryspayeva D, Seyhan AA, Purcell C, MacDonald WJ, Mu K, and El-Deiry WS contributed to data analysis and interpretation; Smolanka Sr I and El-Deiry WS critically reviewed the manuscript. All authors have read and approved the final manuscript.
Institutional review board statement: The study was approved by the Local Ethics Committee of the National Cancer Institute of Ukraine (approval No. 81, issued on May 5, 2016).
Clinical trial registration statement: Not applicable. This study is not a clinical trial.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: De-identified data generated and analyzed during this study are available from the corresponding author upon reasonable request.
Corresponding author: Dinara Ryspayeva, MD, PhD, Assistant Professor, Legorreta Cancer Center, Brown University, 70 Ship Street, Providence, RI 02903, United States. dinara_ryspayeva@brown.edu
Received: October 15, 2025
Revised: November 19, 2025
Accepted: March 2, 2026
Published online: April 24, 2026
Processing time: 190 Days and 14 Hours
Revised: November 19, 2025
Accepted: March 2, 2026
Published online: April 24, 2026
Processing time: 190 Days and 14 Hours
Core Tip
Core Tip: This longitudinal study profiles matched tumor and plasma microRNAs dynamics in breast cancer patients before and after neoadjuvant chemotherapy. By integrating tissue-plasma signatures with survival data, stratified by hormone receptor status, we identified miR-34a and miR-373as independent prognostic markers at diagnosis. Furthermore, miR-137 was identified as candidate predictor of chemosensitivity. Our findings reveal that chemotherapy induces significant “molecular remodeling” and expression convergence across the cohort, which diminishes the prognostic clarity of markers post-treatment. Consequently, our data suggest that baseline profiling offers superior prognostic utility. These findings underscore the critical role of temporal context in microRNA-guided precision oncology and highlight the intricate interplay between systemic and intratumoral molecular landscapes.